Cat:GMP-V-2019nCoV-SnAb002
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-V-2019nCoV-SnAb002 Categories , ,

Description

Cat No.

GMP-V-2019nCoV-SnAb002

Products Name

Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)

Expression platform

Mammalian (human cell)

Isotypes

human IgM

Bioactivity validation

Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.

Source

Mammalian (human cell)

Products description

Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM):GMP-V-2019nCoV-SnAb002, is a potency validated COVID-19 SARS-CoV-2 neutralizing antibody.This This antibodies can either act as positive control in COVID-19 related vaccines and neutralizing antibodies discovery and development, or act as a benchmark in SARS-CoV-2 neutralization potency assay. GeneMedi’s validated COVID-19 neutralizing antibodies group including:GMP-V-2019nCoV-SnAb001(human IgG1),GMP-V-2019nCoV-SnAb002(human IgM),GMP-V-2019nCoV-SnAb003(human IGA),GMP-V-2019nCoV-SnAb004(mouse IgG1),and GMP-V-2019nCoV-SnAb005(Cynomolgus (Non human primate, NHP) IgG1).

Purity

Purity: ≥95% (SDS-PAGE)

Application

positive control in COVID-19 related vaccines and neutralizing antibodies discovery, also act as a benchmark in SARS-CoV-2 neutralization potency assay.

Predicted Molecular Mass

positive control in COVID-19 related vaccines and neutralizing antibodies discovery, also act as a benchmark in SARS-CoV-2 neutralization potency assay.

Formulation

Lyophilized from sterile PBS, PH 7.4

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.